Antibodies and molecules derived therefrom that bind to STEAP-1 proteins

Patent metadata

Field	Value
Publication number	US-9617346-B2
Application number	US-201514604658-A
Country	US
Kind code	B2
Filing date	Jan 23, 2015
Priority date	Apr 22, 2004
Publication date	Apr 11, 2017
Grant date	Apr 11, 2017

Abstract

Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.

First claim

The invention claimed is:

1. An isolated polynucleotide encoding a monoclonal antibody that binds to the STEAP-1 protein of SEQ ID NO:3, wherein the antibody comprises all heavy and light chain complementarity determining regions (CDRs) from the antibody designated X120.545.1.1 (ATCC Accession number PTA-5803).

2. The isolated polynucleotide of claim 1 , wherein the monoclonal antibody is the monoclonal antibody designated X120.545.1.1 (ATCC Accession number PTA-5803).

3. The isolated polynucleotide of claim 1 , wherein the monoclonal antibody is a humanized antibody.

4. The isolated polynucleotide of claim 1 , wherein the monoclonal antibody is an antigen binding antibody fragment.

5. The isolated polynucleotide of claim 4 , wherein the antibody fragment is an Fab, F(ab′)2, Fv or Sfv fragment.

6. An isolated polynucleotide encoding a monoclonal antibody which is a humanized form of the monoclonal antibody designated X120.545.1.1 (ATCC Accession number PTA-5803), wherein the monoclonal antibody specifically binds to the STEAP-1 protein of SEQ ID NO:3.

7. An isolated polynucleotide encoding a recombinant protein comprising the antigen binding fragment of a monoclonal antibody that binds to the STEAP-1 protein of SEQ ID NO:3, wherein the antibody comprises all heavy and light chain complementarity determining regions (CDRs) from the antibody designated X120.545.1.1 (ATCC Accession number PTA-5803).

8. An isolated polynucleotide encoding a recombinant protein comprising the antigen binding fragment of a monoclonal antibody which is a humanized form of the monoclonal antibody designated X120.545.1.1 (ATCC Accession number PTA-5803), wherein the monoclonal antibody specifically binds to the STEAP-1 protein of SEQ ID NO:3.

9. An isolated vector comprising the polynucleotide of claim 1 .

10. An isolated vector comprising the polynucleotide of claim 6 .

11. An isolated vector comprising the polynucleotide of claim 7 .

12. An isolated vector comprising the polynucleotide of claim 8 .

13. An isolated host cell comprising the vector of claim 9 .

14. An isolated host cell comprising the vector of claim 10 .

15. An isolated host cell comprising the vector of claim 11 .

16. An isolated host cell comprising the vector of claim 12 .

Assignees

• Agensys Inc

Inventors

• Jakobovits Aya
• Etessami Soudabeh
• Challita-Eid Pia M
• Perez-Villar Juan J
• Morrison Karen J
• Jia Xiao-Chi
• Faris Mary
• Gudas Jean
• Raitano Arthur B

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K47/6861

  the tumour determinant being from kidney or bladder cancer cell · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61K2039/505

  comprising antibodies · CPC title